The Outcome of Fatherhood in Patients with Philadelphia Negative Myeloproliferative Neoplasms, a Single Institution Experience

• Published in: Blood 2021-11, Vol.138 (Supplement 1), p.4625-4625
• Main Authors: Ali, Elrazi Awadelkarim, Abu-Tineh, Mohammad, Hailan, Yousef, Al-maharmeh, Qusai Ali, Maat, Zakaria Omar, Babiker, Anas M, Ali, Bashir, Ismail, Abdellatif Salah, Yassin, Mohamed A
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2021-145245

▪ Introduction Fertility is a complicated subject, it involves more than one individual, and it has profound psychological and economic implications. Moreover, it is affected by several factors, including age, presence of systemic disease, exposure to environmental toxins, medications, or radiation. Compared to the general population, fertility in patients with malignancy is a more complex topic. Cancer survivors, both male and female, may have reduced fertility due to cancer itself or the treatment received. This includes patients with Myeloproliferative neoplasms (MPN), especially that more patients are diagnosed at younger age and patients had good survival and quality of life. As a result, questions regarding fertility and fatherhood are rising, and the effect of the disease and treatment on male fertility is a big concern. There are limited studies that assessed fatherhood in Philadelphia-negative myeloproliferative neoplasms. Methods This is a single-center, mixed-design study (retrospective + phone interviews) conducted within the National Center for Cancer Care and Research. The aim is to evaluate fertility in the Philadelphia-negative MPN male patients and the effect of treatment received on male fertility and the outcome. Inclusion Criteria: Male patients, adult male patients aged >=18 years old, diagnosed with Philadelphia negative MPN (ET PV MF PMF) According to 2008 2016 WHO criteria and actively receiving treatment including tyrosine kinase inhibitors including (hydroxyurea, interferon, and ruxolitinib ) with the following: -patients with no previous fertility problems will be included in the study. -Patients with no known issues with regards to fertility (fertility is intact) will be included in the study. -Patients who developed fertility issues after diagnosis of Philadelphia negative MPN (ET PV MF PMF), who has been evaluated by an andrologist, and evaluation concluded it is related to treatment. Exclusion criteria: - Patient with Philadelphia positive MPN - Patients not fulfilling inclusion criteria are as follow: -Patient was known to have infertility before the diagnosis of Philadelphia-negative MPN. -Patient with infertility after Diagnosis of Philadelphia negative MPN (ET PV MF PMF): 1.If a Clear underlying cause of infertility is not related to treatment, participants will be excluded from the study.2.if no evaluation was done for infertility or no clear cause for infertility, the patient will be excluded.3.The mother has documentat